2.55
1.59%
0.04
アフターアワーズ:
2.60
0.05
+1.96%
前日終値:
$2.51
開ける:
$2.45
24時間の取引高:
13.68M
Relative Volume:
1.70
時価総額:
$694.95M
収益:
$188.87M
当期純損益:
$-400.38M
株価収益率:
-2.0079
EPS:
-1.27
ネットキャッシュフロー:
$-260.90M
1週間 パフォーマンス:
+23.79%
1か月 パフォーマンス:
+48.26%
6か月 パフォーマンス:
+39.34%
1年 パフォーマンス:
-64.68%
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
名前
Pacific Biosciences Of California Inc
セクター
電話
650-521-8000
住所
1305 O'BRIEN DRIVE, MENLO PARK, CA
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-12-14 | 開始されました | Guggenheim | Neutral |
2023-12-14 | 開始されました | Stephens | Overweight |
2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
2023-11-17 | アップグレード | UBS | Neutral → Buy |
2023-10-31 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
2023-09-28 | 開始されました | Bernstein | Outperform |
2023-07-05 | 再開されました | JP Morgan | Overweight |
2023-06-30 | 開始されました | Goldman | Buy |
2023-05-10 | 開始されました | Barclays | Equal Weight |
2023-03-31 | アップグレード | TD Cowen | Market Perform → Outperform |
2023-02-02 | 開始されました | UBS | Neutral |
2023-01-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
2022-01-21 | 再開されました | Cantor Fitzgerald | Overweight |
2022-01-06 | 再開されました | Piper Sandler | Neutral |
2021-10-15 | 再開されました | Cowen | Market Perform |
2021-09-27 | 開始されました | Canaccord Genuity | Buy |
2021-02-11 | アップグレード | Piper Sandler | Neutral → Overweight |
2020-11-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
2020-10-02 | アップグレード | JP Morgan | Neutral → Overweight |
2020-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
2020-06-02 | 再開されました | Cantor Fitzgerald | Overweight |
2020-03-09 | 再開されました | Cantor Fitzgerald | Overweight |
2019-10-15 | アップグレード | Piper Jaffray | Neutral → Overweight |
2019-04-02 | ダウングレード | Stephens | Overweight → Equal-Weight |
2018-10-19 | 開始されました | Cowen | Outperform |
2017-11-03 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
2017-09-28 | ダウングレード | CL King | Buy → Neutral |
2016-11-03 | 繰り返されました | Cantor Fitzgerald | Buy |
2016-06-27 | 開始されました | CL King | Buy |
2016-04-15 | 開始されました | First Analysis Sec | Overweight |
2016-02-04 | ダウングレード | Piper Jaffray | Overweight → Neutral |
2016-01-04 | 繰り返されました | Cantor Fitzgerald | Buy |
2015-10-23 | アップグレード | Piper Jaffray | Neutral → Overweight |
2015-08-27 | 開始されました | Cantor Fitzgerald | Buy |
2015-02-04 | 繰り返されました | Maxim Group | Buy |
2013-09-26 | 繰り返されました | Maxim Group | Buy |
2013-01-14 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Pacific Biosciences Of California Inc (PACB) 最新ニュース
Vanguard Group Inc's Strategic Reduction in Pacific Biosciences of California Inc - GuruFocus.com
Reasons to Retain PacBio Stock in Your Portfolio for Now - MSN
Curious about Pacific Biosciences (PACB) Q3 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance
Assenagon Asset Management S.A. Trims Stock Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors - Yahoo Finance
Pacific Biosciences of California (PACB) Scheduled to Post Earnings on Thursday - MarketBeat
Pacific Biosciences (PACB): Promising Gene Editing Stock With Innovating Technology - Insider Monkey
Volta Labs joins PacBio Compatible program to help PacBio customers scale sequencing through automated library prep - Quantisnow
Pacific Biosciences of California (NASDAQ:PACB) Shares Up 5.7%Should You Buy? - MarketBeat
PacBio unveils new sequencing chemistry to cut costs By Investing.com - Investing.com Canada
PacBio Announces SPRQ Chemistry for Revio Sequencing Systems, a Major Advance Reducing the Cost of a HiFi Human Genome to less than $500 - Quantisnow
Pacific Biosciences of California, Inc. (NASDAQ:PACB) is a favorite amongst institutional investors who own 86% - Yahoo Finance
PACB (Pacific Biosciences of California) Cash-to-Debt : 0.55 (As of Jun. 2024) - GuruFocus.com
PacBio Onso™ Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program - StockTitan
PacBio Shares Rise After NCCS Partnership for Cancer Genomics Research - MSN
Pacific Biosciences of California (PACB) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Pacific Biosciences of California (NASDAQ:PACB) Trading Down 4.8%Here's Why - MarketBeat
Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt? - Simply Wall St
Brokerages Set Pacific Biosciences of California, Inc. (NASDAQ:PACB) PT at $4.50 - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap DownHere's Why - MarketBeat
Dimensional Fund Advisors LP Sells 2,121,331 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
PacBio inks cancer research deal with Singapore's NCCS By Investing.com - Investing.com South Africa
PacBio inks cancer research deal with Singapore's NCCS - Investing.com India
Pacific Biosciences of California (NASDAQ:PACB) Trading 18.4% HigherHere's Why - MarketBeat
PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing - StockTitan
PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024 - GlobeNewswire
Squarepoint Ops LLC Purchases Shares of 524,608 Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Marshall Wace LLP Raises Stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) - MSN
PacBio, A*STAR, and Macrogen Unveil State-of-the-Art Lab to Accelerate Genomics Innovation in Singapore - StockTitan
PacBio's SWOT analysis: genomics firm faces headwinds, seeks growth - Investing.com
PacBio Grants Equity Incentive Award to New Employee - Quantisnow
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Sold by Oracle Investment Management Inc. - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down to $2.04 - MarketBeat
Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely - Simply Wall St
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives $4.50 Average Price Target from Analysts - MarketBeat
RNA sequencing with Kinnex kits transforms University of Southampton rare disease research - Pacific Biosciences
A stock that deserves closer examination: Pacira BioSciences Inc (PCRX) - US Post News
OrbiMed Advisors sells shares of Passage Bio worth over $146,000 - Investing.com
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Up to $1.87 - MarketBeat
Stocks of Pacific Biosciences of California Inc (PACB) are poised to climb above their peers - SETE News
Riding the Waves: A Guide to Investing in PCRX Stock - The InvestChronicle
Processa Pharmaceuticals (NASDAQ:PCSA) Stock Price Down 0.7% - Defense World
Health Check: Paradigm receives FDA guidance on proposed trial for dodgy knees - Stockhead
Guess which ASX biotech stock is surging 11% on big FDA news - The Motley Fool Australia
Analysts review Pacira BioSciences Inc’s rating - Knox Daily
The time has not yet come to remove your chips from the table: PACS Group Inc. (PACS) - SETE News
Insider’s View: Deciphering Pacira BioSciences Inc (PCRX)’s Financial Health Through Ratios - The Dwinnex
Pacific Biosciences of California Inc’s Mixed Bag: Down -51.19% in 6 Months, Down 9.47% in 30 Days - The InvestChronicle
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Purchased by Daiwa Securities Group Inc. - Defense World
Pacific Biosciences Of California Inc (PACB) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):